V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210036181 | 210013567 | 1.64 | 87.6 | Curative (C) | 2015-11-27 | 2015-12-17 | Cytarabine Intrathecal (any age) | 02 | N | 210041470 | PENTOSTATIN + RITUXIMAB |
| 210036182 | 210028105 | 1.86 | 70.8 | Palliative (P) | 2015-09-06 | 2015-10-02 | Abiraterone | 2 | N | 210041630 | CABAZITAXEL |
| 210036183 | 210013623 | 1.62 | 49 | Curative (C) | 2019-11-30 | 2020-02-06 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE SULPHATE | N | N | 210041817 | UKALL2003 |
| 210036184 | 210022512 | 1.82 | 75.6 | Palliative (P) | 2016-09-29 | 2016-09-29 | Dactinomycin + Vincristine | 2 | Y | 210041854 | NHL 2003 |
| 210036185 | 210013631 | 1.87 | null | null | null | 2016-09-27 | Maintenance Therapy ALL | 2 | N | 210041861 | VINORELBINE |
| 210036186 | 210022531 | 0 | 15.5 | Curative (C) | null | 2017-03-30 | DAUNORUBICIN + VINCRISTINE | 02 | N | 210042069 | DAUNORUBICIN |
| 210036187 | 210013673 | null | 86.5 | null | null | 2018-12-05 | Maintenance Therapy ALL | N | null | 210000284 | MELPHALAN |
| 210036188 | 210013710 | 1.67 | 6.25 | Curative (C) | 2018-09-24 | 2019-01-29 | Cytarabine intrathecal | N | N | 210021324 | IVAC |
| 210036189 | 210022576 | 1.84 | 18.1 | Curative (C) | 2017-11-06 | 2017-11-07 | FCR IV - Cycle 2 onwards | N | N | 210023716 | HYDROXYCARBAMIDE |
| 210036190 | 210013786 | 1.73 | 70.2 | Adjuvant (A) | 2017-12-13 | 2018-08-04 | DAUNORUBICIN + VINCRISTINE | 1 | N | 210028705 | ABVD |
| 210036191 | 210013798 | null | 78.5 | Curative (C) | 2018-08-24 | 2018-09-24 | CARBO + ETOPOSIDE + VINCRISTINE | 02 | N | 210029239 | OFATUMUMAB |
| 210036192 | 210013805 | 1.83 | 117.5 | Curative (C) | null | 2016-11-19 | Nilotinib | N | N | 210029552 | MYELOMA XI TRIAL |
| 210036193 | 210013807 | 1.81 | 39.5 | Disease modification (D) | 2016-02-26 | 2016-07-23 | PACLITAXEL | 2 | N | 210029666 | CYTARABINE HIGH DOSE |
| 210036194 | 210013814 | null | 0 | Curative (C) | 2019-05-17 | 2019-06-24 | Eribulin | 02 | null | 210030225 | VEDEX |
| 210036195 | 210022628 | 1.82 | 63.8 | Palliative (P) | 2018-11-24 | 2019-08-14 | CNS Medbl Std Risk Maint Cisplatin | N | N | 210030551 | CLARITY TRIAL |
| 210036196 | 210013842 | 1.83 | 17.7 | Palliative (P) | 2017-10-14 | 2017-10-22 | CYCLET | 02 | N | 210031205 | DAUNORUBICIN + VNCRISTINE |
| 210036197 | 210031578 | null | null | Curative (C) | 2018-02-07 | 2018-11-04 | Nilotinib | N | null | 210031222 | CAPECITABINE |
| 210036198 | 210013882 | 0 | 59.2 | Curative (C) | 2017-11-07 | 2017-11-21 | AML 19 TRIAL | 2 | N | 210033322 | PEMETREXED |
| 210036199 | 210028225 | 0 | 78.9 | Curative (C) | 2020-03-31 | 2020-04-28 | Cyclophos + Dex + Lenalidomide | Y | N | 210034315 | FLUDARABINE |
| 210036200 | 210013931 | 1.6 | 88.6 | Disease modification (D) | 2018-09-26 | 2018-10-24 | CLARITY Trial | N | N | 210035201 | IBRUTINIB + RITUXIMAB |
| 210036201 | 210013941 | 1.67 | 52.3 | Palliative (P) | 2016-07-20 | 2016-07-26 | CLL210 TRIAL | Y | N | 210035533 | IGEV R |
| 210036202 | 210031600 | 1.57 | 25.5 | Curative (C) | 2018-02-14 | 2018-02-17 | FLAG | Y | N | 210036454 | CLL210 TRIAL |
| 210036203 | 210013979 | 1.72 | 103.4 | Curative (C) | 2019-03-21 | 2019-12-01 | Capecitabine | N | null | 210037672 | LOMUSTINE + VINCRISTINE |
| 210036204 | 210028255 | 1.7 | 77 | null | 2015-03-28 | 2015-04-04 | Alemtuzumab + Cyclophos TBI Allo | N | N | 210039506 | CYTARABINE INTRATHECAL |
| 210036205 | 210014016 | 1.53 | 74 | Disease modification (D) | 2018-03-28 | 2018-03-31 | Packer Induction Vincristine + RT | 02 | Y | 210040040 | ABVD |
| 210036206 | 210014048 | null | 64 | Disease modification (D) | 2020-02-12 | 2020-02-13 | PENTOSTATIN + RITUXIMAB | null | null | 210041755 | ALL |
| 210036207 | 210014051 | null | 19.3 | Disease modification (D) | 2019-04-23 | 2019-04-23 | BOSUTINIB | N | null | 210041781 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210036208 | 210014081 | null | 66.3 | Curative (C) | 2018-06-15 | 2018-09-15 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | 210034307 | CYTARABINE INTRATHECAL |
| 210036210 | 210004328 | 1.7 | 78 | Adjuvant (A) | null | 2015-06-03 | Temozolomide 200mg/m2 | N | N | 210000208 | TEMOZOLOMIDE |
| 210036211 | 210004377 | 1.77 | 78 | Palliative (P) | 2017-10-31 | 2018-04-01 | Temozolomide 200mg/m2 | N | null | 210000395 | TEMOZOLOMIDE |
| 210036212 | 210004391 | 0 | 74.4 | Adjuvant (A) | 2017-06-18 | 2017-09-18 | Temozolomide 200mg/m2 | N | Y | 210000497 | TEMOZOLOMIDE |
| 210036213 | 210004402 | 1.65 | 68 | Adjuvant (A) | 2008-03-01 | 2014-06-11 | Temozolomide 150mg/m2 | N | N | 210000561 | TEMOZOLOMIDE |
| 210036214 | 210004406 | null | 72.2 | Adjuvant (A) | 2016-08-18 | 2016-12-17 | Temozolomide 200mg/m2 | 2 | N | 210000602 | TEMOZOLOMIDE |
| 210036215 | 210038311 | 1.72 | 55.1 | null | 2016-11-30 | 2017-03-18 | Temozolomide 200mg/m2 | N | N | 210000612 | TEMOZOLOMIDE |
| 210036216 | 210004409 | 1.55 | null | Adjuvant (A) | 2016-01-16 | 2016-04-08 | TEMOZOLOMIDE | 2 | N | 210000666 | TEMOZOLOMIDE |
| 210036217 | 210032436 | null | 119.8 | Adjuvant (A) | 2016-12-16 | 2017-03-04 | Temozolomide 200mg/m2 | N | N | 210000818 | TEMOZOLOMIDE |
| 210036218 | 210024739 | null | 52.9 | Adjuvant (A) | 2014-09-16 | 2014-09-22 | TEMOZOLOMIDE | N | N | 210001063 | TEMOZOLOMIDE |
| 210036219 | 210004511 | 1.58 | 91.2 | Adjuvant (A) | 2019-10-05 | 2020-01-19 | Temozolomide 200mg/m2 | N | N | 210001305 | TEMOZOLOMIDE |
| 210036220 | 210004530 | 1.71 | 67 | Palliative (P) | 2014-06-27 | 2014-10-28 | Temozolomide 150mg/m2 | N | N | 210001469 | TEMOZOLOMIDE |
| 210036221 | 210032466 | 1.8 | 70.95 | Curative (C) | 2015-12-21 | 2016-04-10 | TEMOZOLOMIDE | 02 | N | 210001570 | TEMOZOLOMIDE |
| 210036222 | 210004564 | 1.71 | null | Palliative (P) | 2016-09-03 | 2016-09-04 | TEMOZOLOMIDE | 02 | null | 210001686 | TEMOZOLOMIDE |
| 210036225 | 210017381 | null | null | Palliative (P) | null | 2014-06-01 | TEMOZOLOMIDE | N | N | 210002085 | TEMOZOLOMIDE |
| 210036226 | 210024814 | null | 87.9 | Curative (C) | 2014-03-04 | 2014-05-21 | Temozolomide 200mg/m2 | Y | N | 210002344 | TEMOZOLOMIDE |
| 210036227 | 210029539 | 1.83 | null | Curative (C) | 2019-04-29 | 2019-08-06 | Temozolomide 150mg/m2 | N | N | 210002644 | TEMOZOLOMIDE |
| 210036228 | 210037774 | 1.68 | 50 | Curative (C) | 2017-05-27 | 2017-08-10 | TEMOZOLOMIDE | 02 | null | 210002681 | TEMOZOLOMIDE |
| 210036229 | 210004761 | 1.75 | 106.9 | Adjuvant (A) | 2015-01-30 | 2015-05-22 | TEMOZOLOMIDE | 2 | N | 210002776 | TEMOZOLOMIDE |
| 210036230 | 210035751 | 1.71 | 89.8 | Curative (C) | null | 2015-12-17 | Temozolomide 150mg/m2 | N | N | 210002863 | TEMOZOLOMIDE |
| 210036231 | 210004797 | 1.72 | 62 | Palliative (P) | 2014-08-03 | 2014-11-02 | Temozolomide 150mg/m2 | N | N | 210002975 | TEMOZOLOMIDE |
| 210036232 | 210017477 | 1.61 | 82.3 | Curative (C) | 2017-10-24 | 2017-10-25 | Temozolomide 200mg/m2 | 02 | N | 210003399 | TEMOZOLOMIDE |
| 210036233 | 210017493 | 1.81 | 84 | Disease modification (D) | 2018-04-24 | 2018-08-02 | TEMOZOLOMIDE | 02 | N | 210003544 | TEMOZOLOMIDE |